Osteonectin Promoter-Mediated Suicide Gene Therapy of Prostate Cancer

  • Wan-Chi Hsiao
  • Shian-Ying Sung
  • Leland W. K. Chung
  • Chia-Ling HsiehEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1895)


Suicide gene therapy using the herpes simplex virus thymidine kinase (HSV-tk) gene, combined with the prodrug ganciclovir (GCV) medication, is a promising approach for the treatment of malignant tumors, including prostate cancer. The success of this therapeutic strategy requires tissue- or tumor-specific gene expression and efficient gene delivery. In this chapter, we describe the experimental protocols of key methodologies, including promoter construction, reporter assay, adenoviral vector construction and preparation, HSV-tk enzymatic assay and cytotoxicity assay to evaluate the specificity and efficacy of osteonectin promoter-mediated HSV-tk/GCV suicide gene therapy of prostate cancer.

Key words

Osteonectin promoter construction Suicide gene therapy Prostate cancer Adenoviral vector HSV-tk enzymatic assay 



This work was financially supported in part by the Ministry of Science and Technology in Taiwan (Grant No. 106-2320-B-038-055, 106-2320-B-038-056 and 107-2113-M-038-057), and the “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE).


  1. 1.
    Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F (2017) Bone metastases: an overview. Oncol Rev 11(1):321CrossRefGoogle Scholar
  2. 2.
    Muralidharan A, Smith MT (2013) Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology 21(5):339–363CrossRefGoogle Scholar
  3. 3.
    Sung SY, Chang JL, Chen KC, Yeh SD, Liu YR, Su YH, Hsueh CY, Chung LW, Hsieh CL (2016) Co-targeting prostate cancer epithelium and bone stroma by human osteonectin-promoter-mediated suicide gene therapy effectively inhibits androgen-independent prostate cancer growth. PLoS One 11(4):e0153350CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Wan-Chi Hsiao
    • 1
  • Shian-Ying Sung
    • 1
    • 2
    • 4
  • Leland W. K. Chung
    • 3
  • Chia-Ling Hsieh
    • 1
    • 4
    Email author
  1. 1.The Ph.D. Program for Translational Medicine, College of Medical Science and TechnologyTaipei Medical UniversityTaipeiTaiwan
  2. 2.Joint Clinical Research Center, Office of Human ResearchTaipei Medical UniversityTaipeiTaiwan
  3. 3.Uro-oncology Research ProgramSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical CenterLos AngelesUSA
  4. 4.TMU Research Center of Cancer Translational MedicineTaipei Medical UniversityTaipeiTaiwan

Personalised recommendations